Insurance alone didn’t guarantee adherence to Ozempic, study finds

Having insurance coverage alone doesn’t guarantee that people can afford or would be willing to pay continuously for chronic disease medications like Ozempic, a new large-scale study finds.

Looking at insured patients with type 2 diabetes and heart failure, researchers found that people with higher prescription copayments were less likely to consistently take glucagon-like peptide-1 receptor agonists (GLP-1) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) – two classes of drugs that yield additional, long-term benefits compared with older treatments but are also costlier.

Read the rest…

Read Original Article: Insurance alone didn’t guarantee adherence to Ozempic, study finds »